Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice

Journal of Negative Results in Biomedicine

Simone de Vasconcelos Generoso⁴  Flaviano dos Santos Martins¹  Cláudia Martins Carneiro²  Simone Odilia Fernandes³  Valbert Nascimento Cardoso³  Nivea Carolina Paiva²  Michelle Nobre Dias⁴  Brenda de Melo Silva⁴  Tatiani Uceli Maioli⁴ 

[1] Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil;Núcleo de Pesquisa em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto 35400-000, Brazil;Departamento de Análises Clínicas e Toxicológicas, Escola de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil;Departamento de Nutrição, Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil

关键词: Intestinal permeability;    Saccharomyces boulardii;    5-fluorouracil;    Mucositis;    Probiotic;   

Others  :  811157
DOI  :  10.1186/1477-5751-13-6

 received in 2014-01-16, accepted in 2014-04-07,  发布年份 2014

【 摘 要 】

Background

The antimetabolite chemotherapy 5-Fluorouracil is one of the most commonly prescribed drugs in clinical cancer treatment. Although this drug is not specific for cancer cells and also acts on healthy cells, it can cause mucositis, a common collateral effect. Dysbiosis has also been described in 5-fluorouracil-induced mucositis and is likely to contribute to the overall development of mucositis. In light of this theory, the use of probiotics could be a helpful strategy to alleviate mucositis. So the aim of this study was evaluate the impact of the probiotic Saccharomyces boulardii in a model of mucositis.

Results

After induced of mucositis, mice from the Mucositis groups showed a decrease in food consumption (p < 0.05) and therefore had a greater weight loss (p < 0.05). The treatment with Saccharomyces boulardii did not reverse this effect (p > 0.05). Mucositis induced an increase in intestinal permeability and intestinal inflammation (p < 0.05). There were no differences in mucosal lesions, intestinal permeability and sIgA secretion (p > 0.05) in mice pretreated with S. boulardii.

Conclusions

S. boulardii was not able to prevent the effects of experimental mucositis induced by 5- Fluorouracil.

【 授权许可】

   
2014 Maioli et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Prisciandaro LD, Geier MS, Chua AE, Butler RN, Cummins AG, Sander GR, Howarth GS: Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage. Support Care Cancer 2012, 20:3205-3210.
• [2]Harris DJ: Cancer treatment-induced mucositis pain: strategies for assessment and management. Ther Clin Risk Manag 2006, 2:251-258.
• [3]Harris SM, Mistry P, Freathy C, Brown JL, Charlton PA: Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Br J Cancer 2005, 92:722-728.
• [4]Lopes NN, Plapler H, Lalla RV, Chavantes MC, Yoshimura EM, da Silva MA, Alves MT: Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters. Lasers Surg Med 2010, 42:546-552.
• [5]Gibson RJ, Keefe DM: Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006, 14:890-900.
• [6]Keefe DM, Gibson RJ: The combination of oral and small intestinal mucositis, pediatrics and biomarkers: a particularly tricky problem! Cancer Biol Ther 2006, 5:1282-1284.
• [7]Barasch A, Peterson DE: Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 2003, 39:91-100.
• [8]Scully C, Epstein J, Sonis S: Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck 2004, 26:77-84.
• [9]Fata F, Ron IG, Kemeny N, O’Reilly E, Klimstra D, Kelsen DP: 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 1999, 86:1129-1134.
• [10]Soares PM, Mota JM, Gomes AS, Oliveira RB, Assreuy AM, Brito GA, Santos AA, Ribeiro RA, Souza MH: Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Cancer Chemother Pharmacol 2008, 63:91-98.
• [11]Gibson RJ: Gut microbiome and intestinal mucositis: a new challenge for researchers. Cancer Biol Ther 2009, 8:512-513.
• [12]Thom KA, Kleinberg M, Roghmann MC: Infection Prevention in the Cancer Center. Clin Infect Dis 2013, 4:579-585.
• [13]Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Hamilton J, Keefe DM: Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 2009, 234:430-441.
• [14]Generoso SV, Viana M, Santos R, Martins FS, Machado JA, Arantes RM, Nicoli JR, Correia MI, Cardoso VN: Saccharomyces cerevisiae strain UFMG 905 protects against bacterial translocation, preserves gut barrier integrity and stimulates the immune system in a murine intestinal obstruction model. Arch Microbiol 2010, 192:477-484.
• [15]Generoso SV, Viana ML, Santos RG, Arantes RM, Martins FS, Nicoli JR, Machado JA, Correia MI, Cardoso VN: Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr 2011, 50:261-269.
• [16]FAO FaAOotUNaW, World Health Organization: Guidelines For The Evaluation Of Probiotics In Food, Food And Agriculture Organization Of The United Nations & World Health Organization Working Group Report. In Book Guidelines For The Evaluation Of Probiotics In Food, Food And Agriculture Organization Of The United Nations & World Health Organization Working Group Report (Editor Ed.^Eds.). City: FAO/WHO; 2002.
• [17]McFarland LV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
• [18]Liong MT: Safety of probiotics: translocation and infection. Nutr Rev 2008, 66:192-202.
• [19]Elmer GW, McFarland LV: Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001, 30:837-854.
• [20]D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ: Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002, 324:1361.
• [21]Czerucka D, Rampal P: Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 2002, 4:733-739.
• [22]Buts JP, De Keyser N: Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006, 51:1485-1492.
• [23]Prisciandaro LD, Geier MS, Butler RN, Cummins AG, Howarth GS: Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther 2011, 11:671-677.
• [24]Tooley KL, Howarth GS, Lymn KA, Lawrence A, Butler RN: Oral ingestion of Streptococcus thermophilus does not affect mucositis severity or tumor progression in the tumor-bearing rat. Cancer Biol Ther 2011, 12:131-138.
• [25]Whitford EJ, Cummins AG, Butler RN, Prisciandaro LD, Fauser JK, Yazbeck R, Lawrence A, Cheah KY, Wright TH, Lymn KA, Howarth GS: Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther 2009, 8:505-511.
• [26]Jolivet J, Dayan A, Beauchemin M, Chahla D, Mamo A, Bertrand R: Biochemical and Molecular Studies of Human Methenyltetrahydrofolate Synthetase. Oncologist 1996, 1:248-254.
• [27]Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
• [28]Longley DB, Latif T, Boyer J, Allen WL, Maxwell PJ, Johnston PG: The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. Semin Oncol 2003, 30:3-9.
• [29]Sonis ST, Fey EG: Oral complications of cancer therapy. Oncology (Williston Park) 2002, 16:680-686. discussion 686, 691-682, 695
• [30]Howarth GS, Wang H: Role of endogenous microbiota, probiotics and their biological products in human health. Nutrients 2013, 5:58-81.
• [31]Li X, Slayton WB: Molecular mechanisms of platelet and stem cell rebound after 5-fluorouracil treatment. Exp Hematol 2013, 7:635-645,e3.
• [32]dos Santos R, Viana ML, Generoso SV, Arantes RE, Davisson Correia MI, Cardoso VN: Glutamine supplementation decreases intestinal permeability and preserves gut mucosa integrity in an experimental mouse model. JPEN J Parenter Enteral Nutr 2010, 34:408-413.
• [33]Katouzian F, Sblattero D, Not T, Tommasini A, Giusto E, Meiacco D, Stebel M, Marzari R, Fasano A, Ventura A: Dual sugar gut-permeability testing on blood drop in animal models. Clin Chim Acta 2005, 352:191-197.
• [34]Sun Z, Wang X, Andersson R: Role of intestinal permeability in monitoring mucosal barrier function. History, methodology, and significance of pathophysiology. Dig Surg 1998, 15:386-397.
• [35]Mauger CA, Butler RN, Geier MS, Tooley KL, Howarth GS: Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Dig Dis Sci 2007, 52:612-619.
• [36]Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, LaMont JT, Kelly CP: Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001, 69:2762-2765.
• [37]Tsuboi I, Hirabayashi Y, Harada T, Koshinaga M, Kawamata T, Kanno J, Inoue T, Aizawa S: Role of hematopoietic microenvironment in prolonged impairment of B cell regeneration in age-related stromal-cell-impaired SAMP1 mouse: effects of a single dose of 5-fluorouracil. J Appl Toxicol 2008, 28:797-805.
• [38]Vetvicka V, Kincade PW, Witte PL: Effects of 5-fluorouracil on B lymphocyte lineage cells. J Immunol 1986, 137:2405-2410.
• [39]Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC: Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2011, 301:G1083-1092.
• [40]Martins FS, Vieira AT, Elian SD, Arantes RM, Tiago FC, Sousa LP, Araujo HR, Pimenta PF, Bonjardim CA, Nicoli JR, Teixeira MM: Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Microbes Infect 2013, 15:270-279.
• [41]Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC: Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol 2009, 156:78-87.
• [42]Sezer A, Usta U, Cicin I: The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol 2009, 26:350-357.